William T. Hu
Affiliations: | Neurology | Emory University, Atlanta, GA |
Area:
Frontotemporal dementia, Alzheimer's disease, biomarkersGoogle:
"William Hu"Mean distance: 15.07 (cluster 24) | S | N | B | C | P |
Cross-listing: Alzheimer's Tree
Parents
Sign in to add mentor| Virginia Man-Yee Lee | post-doc | University of Pennsylvania School of Medicine | |
| Joseph E. Parisi | post-doc | Mayo Clinc, Rochester | |
| Keith A. Josephs | post-doc | 2004-2008 | Mayo Clinc, Rochester |
| Murray Grossman | post-doc | 2008-2010 | University of Pennsylvania School of Medicine |
| John Q. Trojanowski | post-doc | 2008-2010 | University of Pennsylvania School of Medicine |
| Allan I. Levey | research scientist | Emory |
Children
Sign in to add trainee| Umesh Gangishetti | grad student | Emory | |
| Kathleen McKee | grad student | 2012-2013 | Emory |
| Trung Nguyen | post-doc | Emory | |
| Jennifer Christina Howell | research scientist | 2014-2018 | Emory |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Reus LM, Jansen IE, Tijms BM, et al. (2024) Connecting dementia risk loci to the CSF proteome identifies pathophysiological leads for dementia. Brain : a Journal of Neurology |
| Butts B, Huang H, Hu WT, et al. (2023) sPDGFRβ and neuroinflammation are associated with AD biomarkers and differ by race: The ASCEND Study. Alzheimer's & Dementia : the Journal of the Alzheimer's Association |
| Giannisis A, Al-Grety A, Carlsson H, et al. (2023) Correction: Plasma apolipoprotein E levels, isoform composition, and dimer profile in relation to plasma lipids in racially diverse patients with Alzheimer's disease and mild cognitive impairment. Alzheimer's Research & Therapy. 15: 160 |
| Giannisis A, Al-Grety A, Carlsson H, et al. (2023) Plasma apolipoprotein E levels, isoform composition, and dimer profile in relation to plasma lipids in racially diverse patients with Alzheimer's disease and mild cognitive impairment. Alzheimer's Research & Therapy. 15: 119 |
| Hu WT, Nayyar A, Kaluzova M. (2023) Charting the Next Road Map for CSF Biomarkers in Alzheimer's Disease and Related Dementias. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics |
| van der Ende EL, In 't Veld SGJG, Hanskamp I, et al. (2023) CSF proteomics in autosomal dominant Alzheimer's disease highlights parallels with sporadic disease. Brain : a Journal of Neurology |
| Del Campo M, Peeters CFW, Johnson ECB, et al. (2022) CSF proteome profiling across the Alzheimer's disease spectrum reflects the multifactorial nature of the disease and identifies specific biomarker panels. Nature Aging. 2: 1040-1053 |
| Chan AWS, Cho IK, Li CX, et al. (2022) Cerebral Aβ deposition in an Aβ-precursor protein-transgenic rhesus monkey. Aging Brain. 2 |
| Hok-A-Hin YS, Hoozemans JJM, Hu WT, et al. (2022) YKL-40 changes are not detected in post-mortem brain of patients with Alzheimer's disease and frontotemporal lobar degeneration. Alzheimer's Research & Therapy. 14: 100 |
| Hassan A, Mittal SO, Hu WT, et al. (2022) Does limited EMG denervation in early primary lateral sclerosis predict amyotrophic lateral sclerosis? Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 1-8 |